Related to 2-to-1 Majority of Respondents to a GEN Poll See Smooth Sailing Ahead for Vivus' Obesity Therapy

• Palatin to Receive $5M under Restructured Agreement with AstraZeneca
  
• FASgen Obtains $1.4M NIH Grant to Further Preclinical Obesity Pipeline
  
• Genzyme's Label-Expansion Efforts for ALL Therapy Receive Setback from the FDA
  
• FDA Notifies Spectrum that Its sNDA Does Not Support Fusilev Approval in Colorectal Cancer
  
• FDA's Advisory Panel Gives Approval of Pfizer Drug in First-Line HIV Setting the Thumbs-Up
  
• GSK Obtains FDA Nod for HPV Vaccine
  
• FDA Denies Use of Rituxan in Early Rheumatoid Arthritis
  
• Amgen Set Back with Prolia Approval in Postmenopausal Osteoporosis
  
• GSK’s Seasonal Flu Vaccine Green-Lighted for Use in Children
  
• FDA Clears Abbott’s Rheumatoid Arthritis Test
  
• Arena Reports Positive Data from Phase III Trial with Obesity Therapy
  
• Genmab and GSK Achieve Accelerated FDA Clearance of CLL Drug
  
• FDA Approves AdvanDx’ Faster PNA FISH Protocol for Identifying Enterococcal Bloodstream Pathogens
  
• FDA Grants Emergency Use Authorization to Gen-Probe's PCR Test for the H1N1 Flu
  
• Amylin to Receive $75M in Obesity Alliance with Takeda
  
• FDA Sanctions Gloucester Pharmaceuticals’ Cutaneous T-Cell Lymphoma Therapy
  
• FDA Okays Dyax’ Subcutaneous Kallikrein Inhibitor for Acute HAE
  
• AstraZeneca’s Antidepressant Gets FDA Nod for Label Expansion
  
• Scientists Link Copy Number Variants with Severe Early-Onset Obesity
  
• FDA Approves First Generic Version of Pfizer and Eisai’s Alzheimer Drug